Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Anti-TNFalpha therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.

Original publication

DOI

10.1136/ard.2004.024737

Type

Journal article

Journal

Ann rheum dis

Publication Date

12/2004

Volume

63

Pages

1538 - 1543

Keywords

Antibodies, Monoclonal, Antirheumatic Agents, Arthritis, Rheumatoid, Autoimmune Diseases, Etanercept, Heart Failure, Humans, Immunoglobulin G, Infliximab, Opportunistic Infections, Receptors, Tumor Necrosis Factor, Tumor Necrosis Factor-alpha